))
Much more than a ‘party drug’
Manage episode 365409685 series 3450218
Content provided by EURACTIV. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by EURACTIV or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Psilocybin, MDMA or LSD might associate with party drugs but their therapeutic value is being discovered worldwide. Ian Roullier took part in two clinical trials that looked at the effects of psilocybin on depression. Through his personal experience, Roullier shares his insights on psychedelic-assisted therapy, its potential value to patients and what is needed to boost research in this field.
22 episodes
Share
